Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial

BACKGROUND: Well tolerated antivirals administered early in the course of COVID-19 infection when the viremia is highest could prevent progression to severe disease. Favipiravir inhibits SARS-CoV-2 viral replication in vitro with evidence of clinical benefit in open label trials. Placebo controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: McMahon, James H., Lau, Jillian S.Y., Coldham, Anna, Roney, Janine, Hagenauer, Michelle, Price, Sally, Bryant, Mellissa, Garlick, Jill, Paterson, Anne, Lee, Sue J., O'Bryan, Jess, Hearps, Anna, Tachedjian, Gilda, Pinskier, Henry, Phillips, Cameron, Garrow, Stuart, Pinskier, Nathan, Melvin, Robert, Blakeway, Luke, Wisniewski, Jessica A., Byers, Sally, Badoordeen, Gnei Z., Pereira, Stephanie, Pragastis, Katherine, Trubiano, Jason A., Chua, Kyra Y.L., Kainer, Marion, Molton, James S., Gardiner, Bradley J., Pierce, Anna B., Cheng, Allen, Rogers, Benjamin A., Peleg, Anton Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583769/
https://www.ncbi.nlm.nih.gov/pubmed/36284645
http://dx.doi.org/10.1016/j.eclinm.2022.101703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583769/
https://www.ncbi.nlm.nih.gov/pubmed/36284645
http://dx.doi.org/10.1016/j.eclinm.2022.101703

Ejemplares similares